When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Malignant pleural mesothelioma (MPM) is an aggressive inflammatory cancer with a poor survival rate. Treatment options are limited at best and drug resistance is common. Thus, there is an urgent need to identify novel therapeutic targets in this disease in order to improve patient outcomes and survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Baird, Anne-Marie, Easty, David, Jarzabek, Monika, Shiels, Liam, Soltermann, Alex, Klebe, Sonja, Raeppel, Stéphane, MacDonagh, Lauren, Wu, Chengguang, Griggs, Kim, Kirschner, Michaela B., Stanfill, Bryan, Nonaka, Daisuke, Goparaju, Chandra M., Murer, Bruno, Fennell, Dean A., O'Donnell, Dearbhaile M., Barr, Martin P., Mutti, Luciano, Reid, Glen, Finn, Stephen, Cuffe, Sinead, Pass, Harvey I., Opitz, Isabelle, Byrne, Annette T., O'Byrne, Kenneth J., Gray, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399142/
https://www.ncbi.nlm.nih.gov/pubmed/30863365
http://dx.doi.org/10.3389/fendo.2019.00089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399142/
https://www.ncbi.nlm.nih.gov/pubmed/30863365
http://dx.doi.org/10.3389/fendo.2019.00089

Ejemplares similares